Review
PIV-3 vaccine National Institutes of Health/Aviron
Affiliations
- PMID: 11757785
Item in Clipboard
Review
PIV-3 vaccine National Institutes of Health/Aviron
Curr Opin Investig Drugs.
2001 Jul.
Abstract
Wyeth-Lederle, Aviron and NIH are developing a live intranasal parainfluenza virus (PIV) type 3 vaccine (cp45 vaccine). The vaccine is in phase II/III trials with Aviron [411386], and phase I trials with Wyeth-Lederle [408940]. It consists of a temperature-sensitive PIV-3 virus attenuated with an imported L gene mutation. This addition renders the virus 5-fold more restricted for replication in the respiratory tract of chimpanzees and also more temperature-sensitive [336999].
Similar articles
-
Current status of vaccines for parainfluenza virus infections.Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S123-5. doi: 10.1097/INF.0b013e318168b76f. Pediatr Infect Dis J. 2008. PMID: 18820572 Review.
-
Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.Virology. 1999 Jul 20;260(1):125-35. doi: 10.1006/viro.1999.9802. Virology. 1999. PMID: 10405364
-
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.Pediatr Infect Dis J. 2003 May;22(5):394-405. doi: 10.1097/01.inf.0000066244.31769.83. Pediatr Infect Dis J. 2003. PMID: 12792378 Clinical Trial.
-
Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.J Infect Dis. 2004 Feb 1;189(3):462-70. doi: 10.1086/381184. Epub 2004 Jan 20. J Infect Dis. 2004. PMID: 14745704 Clinical Trial.
-
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007. Drugs R D. 2003. PMID: 12952502 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources